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Cell deathNemaline myopathy is a neuromuscular disorder, characterized by muscle weakness and hypotonia and is, in
20% of the cases, caused by mutations in the gene encoding α-skeletal muscle actin, ACTA1. It is a
heterogeneous disease with various clinical phenotypes and severities. In patients the ultrastructure of
muscle cells is often disturbed by nemaline rods and it is thought this is the cause for muscle weakness. To
search for possible defects during muscle cell differentiation we expressed α-actin mutants in myoblasts and
allowed these cells to differentiate into myotubes. Surprisingly, we observed two striking new phenotypes in
differentiating myoblasts: rounding up of cells and bleb formation, two features reminiscent of apoptosis.
Indeed expression of these mutants induced cell death with apoptotic features in muscle cell culture, using
AIF and endonuclease G, in a caspase-independent but calpain-dependent pathway. This is the ﬁrst report on
a common cellular defect induced by NM causing actin mutants, independent of their biochemical
phenotypes or rod and aggregate formation capacity. These data suggest that lack of type II ﬁbers or atrophy
observed in nemaline myopathy patients may be also due to an increased number of dying muscle cells.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionNemaline myopathy (NM) is a neuromuscular disorder, character-
ized by muscle weakness and hypotonia. It is a heterogeneous disease
in which cases are classiﬁed according to the onset of the illness and
clinical presentation of patients [1,2] ranging from lethality shortly
after birth to having a fairly normal live. NM is a disease of the skeletal
muscle sarcomere and is caused by mutations in some components of
the thin ﬁlament [3] and in particular in α-skeletal muscle actin
(ACTA1, further referred to as α-actin) [4–6]. At the cellular level a
typical phenotype is the presence of rod shaped structures (nemaline
rods) that disturb muscle ultrastructure and that contain actin. They
are either present in the sarcoplasm or in the nuclei of affected muscle
ﬁbers. On this bases NM has been further divided into subclasses [6],
typical nemaline myopathy (NEM) and intranuclear rod myopathy
(IRM) respectively. A third class, actin myopathy (AM), is character-
ized by an excess of thin ﬁlamentous inclusions disturbing the normal
myoﬁbrillar ﬁlament lattice. This division in three classes is, however,
not strict since a number of patients show more than one histologicaly, Ghent University, A. Baert-
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ll rights reserved.phenotype in their muscle biopsies, such as the combination of
intranuclear rods with excess of thin ﬁlament or with cytoplasmic
rods. The rods contain actin and material from Z-lines, mainly α-
actinin 2 [7]. However, their composition and size vary depending on
their subcellular location [8]. Curiously, the proportion of muscle
ﬁbers with rods does not correlate with the degree of muscle
weakness [1].
To date, more than 100 α-actin mutations leading to NM have
been identiﬁed [9,10]. It is not surprising that mutations in this highly
conserved protein cause muscle diseases, given its importance in
striated muscle formation and function, and its complex activities.
Actin requires a special folding pathway, involving the chaperones
prefoldin and the cytoplasmic chaperonin CCT, for functional
maturation [11–13]. It has an absolute requirement for ATP (or
ADP) to remain stable [14]. It self-associates resulting in the
formation of actin ﬁlaments that are part of the cytoskeleton and
that can interact with many actin binding proteins (ABPs), e.g. α-
actinin, troponin and myosin in muscle, thereby contributing to
contractile force generation. As a result, a disease causing mutation in
actin may affect one or more of these properties, and some of these
defects can be unraveled by biochemical tests and/or by ectopic
expression in ﬁbroblasts or myoblasts and early myotubes as shown
in previous studies by us and by others [15–17]. However, there is
little correlation between biochemical behaviour and cell biological
or even clinical observations.
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skeletal actin mutants biochemically and by expression in ﬁbroblasts,
myoblasts and myotubes. Upon expression of two mutants displaying
folding defects (L140P and G146D) in differentiating myoblasts, we
observed two striking new phenotypes: bleb formation at the cell
membrane and rounding up of cells, two features reminiscent of
apoptosis. These features were also observed upon inspection of
differentiating myotubes expressing these or other NM causing actin
mutants. Our results indicate that these mutants induce cell death in
muscle cell culture in a caspase-independent, calpain involved AIF and
endonuclease G pathway. The observed cell death occurs regardless of
the biochemical or cellular phenotypes of the α-actin mutants. Thus
for the ﬁrst time we found a common muscle cell speciﬁc defect
induced by NM causing actin mutants and these data suggest that
atrophy, with a lack of type II ﬁbers, commonly observed in NM
patients may be in part due to increased cell death.
2. Materials and methods
2.1. Construction of the α-actin nemaline myopathy mutants
Mutations were made with the QuikChange site directed muta-
genesis kit (Stratagene) according to the manufacturer's instructions,
using the human ACTA1 cDNA sequence in pcDNA3.1 (Invitrogen) as a
template and appropriate primers. N-terminal myc-tagged wild type
actin and mutants were made by PCR using the actin (mutants) in the
pcDNA3.1 vector as template, a 5′ primer containing the myc-
sequence preceded by a HindIII site and a 3′ primer containing an
XbaI site. These fragments were ligated into HindIII–XbaI digested
pcDNA3.1. pIRES-GFP Wt and mutant constructs were made by PCR
with a 5′ primer containing an XhoI site and a 3′ primer containing a
BamHI site and ligated in the XhoI–BamHI digested pIRES-EFGP2
vector. Constructs were sequenced to verify the complete ACTA1
coding sequence and correct introduction of the desired mutation.
Expression of actin mutants using in vitro translation assays, band
shift assays with actin binding proteins, and copolymerization assays
were performed as described in [16,18].
2.2. Cell culture and transfection
Sol8 myogenic cells [19] were seeded in 12 well plates containing
gelatin-coated glass or thermanox coverslips (Nunc). Myoblasts were
grown in Dulbecco's modiﬁed Eagle medium (DMEM)/HamF-12
medium (Invitrogen) (50:50) supplemented with 10% fetal calf
serum (Invitrogen), 1% L-glutamine, and 1% antibiotics (penicillin-G,
100 IU/ml and streptomycin, 100 μg/ml, Invitrogen). After 24 h the
cells were transfected with the pcDNA3.1 vectors encoding N-
terminally myc-tagged α-skeletal muscle actin (wild type or mutant)
using jetPEI (Qbiogene) or the Effectene transfection reagent (Qiagen)
according to the manufacturer's protocols. To study transfected
myoblasts, coverslips were mounted for immunoﬂuorescence after
48 h of transfection. To promote fusion (F) of myoblasts into
myotubes, the growth medium was replaced by a differentiation
medium (DMEM supplemented with 2% heat-inactivated horse serum
(Invitrogen), 10 μg/ml insulin (Sigma), 1% L-glutamine and 1%
antibiotics, following 2–3 days of proliferation (37 °C, 5% CO2, water-
saturated air) to around 80% of conﬂuence). Myotubes were
immunostained on day F+4. Sometimes myotubes were kept in
culture till 11 days after fusion; they were seeded on thermonax
coverslips and the proliferation medium contained only 0.5% horse
serum and no insulin. Sol8 cells were transfected using the Amaxa cell
line nucleofector kit V, according to the manufacturer's instructions.
We used nucleofection for the transfection experiments since this
resulted in a much higher transfection yield, which is required for
counting dying cells, in order to have statistically reliable data and
interpretations.For primary cultures, satellite cells were isolated from hind limb
muscles of newborn rats. Muscles were minced and washed in a
calcium- and magnesium-free medium (116 mM NaCl; 5 mM KCl;
2.6mMNaHCO3; 8mMNaH2PO4; pH 7.5; 4 °C) and then transferred in
the same medium containing trypsin (250 U/mg, Seromed) for two
rounds of dissociation (10 min and 20 min, respectively; 37 °C) with
continuous stirring. The supernatants were centrifuged (15 min at
4 °C, 700 ×g) and the pellets were resuspended in a 78% HAM F-12
medium, supplemented with 10% fetal calf serum, 10% heat-inactive
horse serum, 1% L-glutamine and 1% antibiotics. The cell suspension
was then ﬁltered on a nylon netting (pore size 21 μm) in culture ﬂasks
and preplated in 100 mm plastic petri-dishes for 40 min (37 °C, 5%
CO2, water-saturated air) to remove most of the adhering non-muscle
cells. Then cells were seeded on laminin-coated glass coverslips in 12
well plates. After 48 h, cells were transfected with the pcDNA3.1
vectors encoding N-terminally myc-tagged α-skeletal muscle actin
(wild type or mutant) using jetPEI (Qbiogene). After 1 day (F) the
growth medium was exchanged for a fusion medium: DMEM
supplemented with 5% heat-inactivated horse serum. Myotubes
were immunostained on day F+4.
2.3. Calculation of fusion index and % of rounded cells
For the calculation of fusion indexes we determined the amount of
nuclei (DAPI staining) in myotubes (phase contrast) and divided this
by the total amount of nuclei. This was done for two independent
experiments and the mean was calculated.
We determined for eachmutant the percentage of round or spindle
shaped blebbing cells of the total transfected (myc or EGFP-positive)
population on a coverslip (∼900 to 3000 cells) after 4 days of
differentiation. We calculated the mean of two independent experi-
ments per mutant.
2.4. Immunological staining
The cultured cells were ﬁxed in TBS/4% paraformaldehyde and
permeabilized with TBS/0.5% Triton X-100. Samples were then
incubated for 1 h with primary antibodies (polyclonal anti-myc
antibody (Abcam) to visualise the mutant actins and a monoclonal
antibody against troponin T (Sigma), or α-actinin (Sigma) to visualise
myoﬁlaments) in TBS (20 mM Tris base, 154 mM NaCl, 2 mM EGTA,
2 mM MgCl2, pH 7.5)/1% BSA (Sigma). After washing in TBS, the cells
were incubated for 30 min in TBS/1% BSA with FITC-conjugated goat
anti-mouse and TRITC-conjugated anti-rabbit secondary antibodies or
TRITC-phalloidin (Jackson Immunoresearch). Samples were mounted
using Vectashield mounting medium (Vector). Nuclei were stained
with the TO-PRO-3 dye (Molecular Probes) or with DAPI (Molecular
probes).
2.5. Detection of apoptosis
Transfected cells were stained for the myc-tagged actin and co-
stained either with a mouse anti-cytochrome c antibody using the
select FX alexa ﬂuor 488 cytochrome c apoptosis detection kit
(Invitrogen), a rabbit anti-cleaved caspase-3, anti-caspase-3, anti-
cleaved caspase-9, anti-caspase-12 or anti-cleaved PARP antibody
(Cell Signalling Technology), a mouse anti-AIF antibody (Santa Cruz
Biotechnology) or a rabbit anti-endo G antibody (Abcam). As a
positive control for apoptosis, cells were incubated for 4 h with 10 μM
camptothecin (Sigma) at 37 °C before staining (data not shown) or
2 μM staurosporin for 24 h. For analysis of ﬂuorescence intensity of
cleaved caspase 3, 5 regions of interest where selected and the mean
ﬂuorescence intensity of every region was measured. The mean of
these 5 averages was calculated.
For Western blots cells were lysed in PBS with 1% Triton X-100,
1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml antipain, 1,6 μg/ml
Fig. 1. (A) Location of the studied ACTA1 mutations on the 3D-representation of the
actin molecule [21]. Mutants indicated in blue are biochemically characterized in this
study; mutants in pink were biochemically characterized in Costa et al. [16]. I–IV
indicate the actin subdomains. ATP is in yellow. The structure was taken from PDB code
1ATN and displayed by ViewerLite. (B) Native gel analysis and autoradiography of seven
35S-labeled α-actin mutants causing NM and WT α-actin. Gels were run without (a) or
with (b) ATP. Actins were produced in in vitro transcription translation reactions in
reticulocyte lysate, which endogenously contains CAP [52] and the actin folding
machinery, prefoldin (PFD) and CCT [11,13,18]. Mutants L140P and G146D remain bound
to CCT and prefoldin under both conditions. The other mutants fold correctly, as
evidenced by the presence of an abundance of folded actin. The different mobilities of
the actins are due to the charge changes introduced bymost of themutations. On the gel
without ATP, mutants α-act A138P, D154N and D179G show a pronounced increase in
binding to CAP indicating they are less stable.
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blotting were used with rabbit anti-caspase 2 (Abcam) or a rabbit
anti-cleaved caspase 3, anti-cleaved caspase-9, anti-caspase-12 or
anti-cleaved PARP antibody (Cell Signalling Technology).
To probe for caspase and calpain activity we added to the
differentiation medium 5 or 10 μM of the pancaspase inhibitor
ZVAD-FMK (promega) or 50 μM PD150606 calpain inhibitor (Calbio-
chem), respectively during 4 days of differentiation.
2.6. Cytoﬂuorescence analysis
Immunolabeled samples were examined using an Olympus IX71
epiﬂuorescence microscope and images were acquired using a cooled
Spot Camera (Diagnostic Instruments) and Analysis software (Soft
Imaging Systems). Images were also acquired using a Zeiss Axioplan
200 M epiﬂuorescence microscope, equipped with an Apotome slider,
a cooled CCD Axiocam Camera and Axiovision 4.4 software. Confocal
laser-scanning microscopy (CLSM) was performed using a Bio-Rad
MRC 1024 ES (Bio-Rad, Hemel Hempstead, UK) equipped with an
argon–krypton gas laser. The TRITC ﬂuorochromewas excitedwith the
568-nm yellow line and the emission was collected via a photo-
multiplier through a 585 long pass ﬁlter, the FITC ﬂuorochrome with
the 488 nm line and collected through the 522 ﬁlter. Nuclei staining
was obtained with the TO-PRO-3 probe and acquired with excitation
at 647 nm and collected through the 680 nm ﬁlter. Additionally, an
Olympus confocal system equipped with an argon–krypton gas laser
was used. The excitation wavelength of 488 nm and 543 nm were
respectively used for acquisition of images in green channel (520 nm)
and in red channel (600 nm). Data were acquired using an inverted
microscope (Olympus IX70) with a ×60 water immersion objective
and processed with the LaserSharp software (version 3.0, Bio-Rad).
The mean ﬂuorescence of myc staining of 38 WT and 40 A138P
actin expressing Sol8 muscle cells (F+4) was measured with the Cell
M software (Olympus).
3. Results
3.1. Biochemical characterization of seven new NM causing α-skeletal
actin mutants
In a previous study [16], we biochemically characterized a set of
actin mutants causing nemaline myopathy and discovered four
different biochemical phenotypes: folding defectivemutants, unstable
mutants, mutants with reduced copolymerisation capacity and
mutants without defects in these tests (for details and limitations of
these assays see [16,18,20]). In the present study, we investigated
seven new mutants using similar approaches. The locations of the
mutations in the actin molecule are displayed in blue on the 3D-
representation of the actin molecule (Fig. 1A) [21]. The mutations
A138P, D154N, D179G and K336I are in or near the nucleotide-binding
pocket, of which A138P and K336I are also in the hinge regions
between actin subdomains 1 and 3, where also the mutations L140P
and G146D are located. Mutation S348L is located in subdomain 1. In
patient muscles, these mutants induce different abnormal structures
such as intranuclear and cytoplasmic rods and/or an excess of thin
ﬁlaments (Table 1).
Biochemical characterization revealed that actin mutants L140P
and G146D display compromised folding (Fig. 1B). The majority of the
synthesized molecules stick to the chaperones CCT and prefoldin. The
few molecules that are released are however correctly folded, since
they can bind to ABPs (Table 1). All other mutants fold properly since
they migrate at a position similar to monomeric actin in gels
containing ATP (Fig. 1B,b) and since they can bind with the ABPs
tested (i.e. thymosin β4, DNAseI and VDBP and adseverin, Table 1).
Mutants α-act A138P, D154N, and D179G show an increase in CAP-
binding on gels without ATP (respectively 28%, 35% and 9% compared
Fig. 2. N-terminally myc-tagged WT α-skeletal muscle actin incorporates normally in
actin structures in myoblasts and myotubes. Myc-tagged WT α-actin colocalises with
stress-ﬁbers in undifferentiated myoblasts (A) and incorporates in peripheric
premyoﬁbrils in differentiating myoblasts (B) and early myotubes (F+4) (C); in more
differentiated myotubes (F+5) myc-actin incorporates in the nascent sarcomeres. (D)
Green is myc staining, red is phalloidin or actinin (D) staining. Images are confocal. Bars,
20 μm.
Table 1
Summary of the biochemical characterization of seven nemaline myopathy causing α-
skeletal muscle actin mutants.
Mutant Phenotype Folding CAP ABP Copol In actin structure Reference
WT + + + ++
+
A138P IRM + +
+
+
+ ++
+
Hinge region 1 [6]
L140P Typical
NEM
Few − + + Hinge region 1 [6]
G146D AM Few − + + Hinge region 1 [51]
D154N AM, IRM + +
+
+
+ ++
++
In ATP cleft [50]
D179G Severe
NEM
+ +
+
+ ++
+
In ATP cleft, stabilizing
interaction with H73
[51]
K336I IRM + + + ++
+
In ATP cleft, ATP-
binding
[6]
S348L AM + − + ++
+
In subdomain 1, at
surface
[6,47]
The properties investigated here are folding, binding to cyclase associated protein
(CAP), binding to the actin binding proteins (ABP) thymosinβ4, DNAseI and vitamin D
binding protein (VDBP) and copolymerisation (copol) with rabbit α-skeletal muscle
actin (copol). Also the position in the actin structure according to Kabsch et al. [21] is
indicated, in addition to the phenotype of the patient as described in the reference, with
AM=actin myopathy, excess of thin ﬁlaments; NEM=nemaline myopathy with
sarcoplasmic nemaline bodies; IRM=intranuclear rod myopathy.
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[12,20], which is consistent with a mutation near the ATP-binding site.
These mutants thus belong to the class of unstable mutants. The
copolymerisation test allowed classifying the remaining mutants α-
act K336I and S348L which show no copolymerisation defect in vitro.
3.2. WT myc-tagged α-skeletal muscle actin incorporates
in myoﬁlaments
To examine the ability of these actin mutants to incorporate into
endogenous actin structures, we expressed N-terminal myc-tagged
versions in Sol8 or primary myoblasts. We allowed them to
differentiate and to fuse into myotubes and analysed the cellular
phenotypes one (F+1), four (F+4) or ﬁve (F+5) days after induction
of differentiation. Occasionally we also used NIH3T3 ﬁbroblasts to
illustrate a difference in behaviour of mutants in ﬁbroblasts and
myogenic cells.
Although undifferentiated myoblasts do not express endogenous
α-actin ectopically, expressed myc-taggedWT α-actin incorporates in
stress-ﬁbers, which mainly consists of β-actin (Fig. 2A). This
observation is consistent with the observation that precocious
expression of α-skeletal muscle actin does not compromise the ability
of myoblasts to form stress-ﬁber like structures [22].
During differentiation the myoblasts become spindle shaped (Fig.
2B, these myoblasts are further referred to as differentiating
myoblasts) and fuse to long myotubes, initially with central nuclei
(Fig. 2C). At this stage the main actin isoform is α-skeletal muscle
actin. Staining for myc shows that ectopic WT α-actin incorporates in
peripheric premyoﬁbrils, but not in the internal phalloidin positive
actin meshwork (Fig. 2B,C). Ectopic α-actin preferentially incorpo-
rates in the α-actin muscle speciﬁc cytoskeleton at more differ-
entiated stages. This is also shown in cells that start to form striations,
where myc-actin is incorporated in the nascent myoﬁlaments
decorated with α-actinin (Fig. 2D).
3.3. Folding compromised mutants do not incorporate into ﬁlamentous
structures in cells and cause small bleb formation
Mutants α-act L140P and G146D do not incorporate in actin ﬁbers
in myoblasts, myotubes or ﬁbroblasts consistent with their foldingdefect observed in vitro. In ﬁbroblasts they also do not form the rods
(Fig. 3) that are typically observed for other NM causing actin
mutants (see [16], and below). Rather these mutants are in phalloidin
negative aggregates in ﬁbroblasts (Fig. 3A) or diffusely localised in
the cytoplasm of undifferentiated myogenic cells (Fig. 3D). Intrigu-
ingly in differentiating myoblasts they induce blebs and these are
devoid of endogenous F-actin and troponin but do contain the
mutant actin (Fig. 3B, E). In addition, in myotubes, both mutants do
not incorporate in actin ﬁlaments, but reside in small speckles
throughout the cytoplasm (Fig. 3C,F). Unlike WT transfected
myotubes that have straight cell walls, L140P and G146D transfected
myotubes occasionally display small blebs, in which mutant actin is
locally enriched (arrows in Fig. 3F).
3.4. Actin mutants cause blebbing or rounding up of muscle cells during
differentiation, independently of their biochemical phenotype
Given that bleb formation may be a new phenotype we
investigated whether muscle cells expressing α-actin mutants with
other biochemical defects (determined in this study or in [16], Fig. 1A)
also display this phenotype during their differentiation. This indeed
appears to be the case for some mutants with compromised ATP-
binding: α-act G15R, A138P, D154N, V163L and D179G, for those with
reduced copolymerisation capacity:α-act I64N, I136M and G268R and
Fig. 4. Themajority ofα-actinmutants appear to induce cell death ofmuscle cells. (A, A′)
Wide ﬁeld view of Myc-stained Sol8 cells at stage F+4. Cells expressing WT myc-
α-actin are normally differentiated to myotubes (A) whereas those expressing Myc-
α-act A138P (A′) are poorly differentiated andmany rounded up cells are observed. The
inset in A′ shows that myc-α-act A138P induces formation of bleb like structures in
differentiating Sol8 myoblasts; Green corresponds to the myc staining and red to α-
actinin staining. (B) Graph indicating the percentage of rounded blebbing α-actin
mutant expressing cells in the transfected populations at stage F+4. The given
percentages are the mean values of two experiments counted separately for the
mutants (7 independent quantiﬁcations for WT). The total number of cells counted per
experiment varies from 900 to 3000. Mutants are grouped by their biochemical defect.
Classiﬁcation in mild, severe and typical NM (indicated by colors) and actin myopathy
(AM) and intranuclear rod myopathy (IRM) are according to Sparrow et al. [6].
Fig. 3. α-actin mutants with folding defects do not incorporate in actin ﬁlaments and
induce bleb formation in muscle cells. (A) NIH3T3 ﬁbroblast, (B) differentiating Sol8
myoblast and (C) Sol 8 myotube (F+4) expressing myc-α-act L140P; (D) undiffer-
entiated Sol8 myoblast, (E) differentiating Sol8 myoblast and (F) Sol8 myotube (F+4)
expressing myc-α-act G146D. Arrows indicate myc positive blebs in differentiating Sol8
myoblasts and Sol8 myotubes. Green is myc staining, red is phalloidin staining in A,D
and E, troponin T staining in B, and α-actinin staining in (C) and (F). (B), (C) and (F) are
confocal images. Bars, 20 μm.
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H40Y, D286G, K336I and S348L (data not shown). In undifferentiated
myoblasts (data not shown) or ﬁbroblasts this phenomenon was
never observed ([16] and Fig. S1).
In addition, wider ﬁeld views indicate that, in contrast to WT
expressing muscle cells that are nicely differentiated, many unfused
cells, transfected with mutant actin, are present at F+4 or F+5. This is
shown for α-act A138P in Fig. 4A (for wider ﬁelds of muscle cellsexpressing other mutants, see Fig. S2). Consistent with this is the
fusion index of myotubes formed after transfection of A138P is
reduced (29.4%) as compared to that of myotubes obtained after WT
actin transfection (38.6%). Most of the α-act A138P expressing single
cells are rounded up or spindle shaped and display blebs. A close up of
such a blebbing cell expressing α-act A138P is shown in the inset in
Fig. 4A′.
To approach this statistically we determined for each mutant the
percentage of round or spindle shaped blebbing cells of the total
transfected population after 4 days of differentiation, which is the
time point where we detected most rounded cells. Inspection of the
graph in Fig. 4B shows that for the majority of NM causing α-actin
mutants differentiating myoblasts display indeed an increased level of
this phenotype compared to WT and mock transfected cells. This is
most striking for myc α-act I136M, A138P, D154N and V163L. In the
latter cases, the amount of rounded cells on day F+4 is approximately
3 to 4 fold higher than for WT α-actin expressing cells. Increased
rounding up, although to a lesser extent, is also observed for cells
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V370F (between 2 and 3-fold more thanWTexpressing cells). Also for
α-actin mutants I64N and K336I the amounts of rounded cells were
still consistently higher than for WT α-actin expressing cells. Two
mutants, α-act G15R and D286G had no signiﬁcantly different levels
of rounded up cells as WT α-actin. In the graph (Fig. 4B), the actin
mutants are grouped per biochemical phenotype, which shows that
the latter does not correlate with the degree of occurrence of the
cellular phenotype. Colours indicate the type of NM the mutant
induces, according to Sparrow et al. [6].
Note that in the set up we used, transfection efﬁciencies, measured
at the myoblast stage, are approximately 60%. Consequently, this
results in a mixed population of myotubes originating from trans-
fected and untransfected myoblasts, perhaps yielding lower estimates
of rounding differentiating myoblasts (compared to a culture with
theoretical 100% transfection efﬁciencies), because of a possible
dilution effect of the mutant actin when transfected cells fuse with
untransfected cells. Additionally, rounded up cells tend to detach from
the substrate ultimately yielding reduced numbers of differentiated
fused cells (compare Fig. 4A and A′) in function of time, whereas the
number of cells at the start of the experiment was equal. Nevertheless
our results suggest that rounding up and blebbing of cells may be a
common phenotype of cells in culture expressing particular NM
causing α-actin mutants and this happens regardless of a particular
biochemical phenotype. To exclude effects of the myc-tag on the
phenotype we expressed, in an independent experiment, untagged
WTand A138P actin in a pIRES-GFP vector in parallel withmyc-tagged
WT actin expressing cells, and performed similar counts. Similar
results were obtained for untagged and myc-tagged actin, and
untagged A138P actin still induced a 4-fold increase in the occurrence
of rounded blebbing cells (Fig. S3). Additionally, to rule out that the
phenotype was induced by an elevated expression level of the mutant
compared to the WT actin, we measured the mean ﬂuorescence of
single cells of parallel myc-stained Sol8 muscle cells at day F+4. Fig.
S3 shows that myc-actin expression levels are similar in WT and
A138P expressing muscle cells (Fig.S3).
3.5. NM causing α-actin mutants induce cell death with apoptotic
features in differentiating muscle cells
Bleb formation and rounding up of cells are two phenotypes
indicative of cell death, more particularly of apoptosis. Therefore we
further investigated if apoptosis was indeed induced, using the α-
actin mutant A138P as a model (for examples of other mutants see
below). We did not detect increased DNA fragmentation (by TUNEL
staining or isolation of genomic DNA) or phosphatidylserine externa-
lization (by annexin V staining) (data not shown). However, we
observed occasionally condensed, fragmented nuclei (Fig. 5A) as well
as the release of cytochrome c in the cytosol which is typical for
apoptosis ([23] and Fig. 5A–C). Rounded up cells expressing the A138P
mutant indeed display increased diffuse cytosolic cytochrome c
staining (Fig. 5B,C), whereas untransfected differentiating cells (Fig.
5B) or WT expressing differentiating cells show a distinct punctuate
mitochondrial staining (Fig. 5D).
In striated muscle cells both a caspase- and a caspase-independent
cell death pathway have been described [24,25]. We probed whether
caspases were activated at early differentiation and myoblast stages
using Western blot and immunohistochemistry; however, we did
not observe elevated cleaved caspase species or products (caspase 3
(Fig. 5I,J, S4), 2, 6, 9 or 12, PARP data not shown). Moreover,
treatment of WT and A138P expressing myotubes with the
pancaspase inhibitor ZVAD-FMK, unexpectedly resulted in increased
numbers of rounding cells in a dose dependent manner (Fig. 5K).
The observed lack of increased caspase activity suggests that mutant
expressing cells may induce the alternative caspase-independent
pathway.In this case, in skeletal muscle, apoptosis inducing factor (AIF) and
endonuclease G (endo G) are released from mitochondria to the
cytosol and translocate, via a stage of perinuclear localization [24] to
the nucleus (reviewed in [23]). Therefore, we performed stainings for
endo G and AIF on the transfected dying cells. We observed indeed
perinuclear and nuclear localisation of AIF and endo G in the round
cells expressing A138P (Fig. 5E, G), and a cytoplasmic staining in WT
expressing cells (Fig. 5F, H).
We additionally tested whether calpain was active in this process,
as it was earlier described to be involved in apoptosis in serum-
deprived satellite cells [26] and to be upstream from AIF [27,28]. We
incubated WT and A138P expressing myotubes with the calpain
inhibitor PD150606, which inhibits both m-calpain and μ-calpain, and
found that this signiﬁcantly decreased the number of rounding,
blebbing cells in A138P expressing cells, whereas it had no effect on
cell death in the WT expressing population (Fig. 5L). This indicates
that cell death is occurring, but via a less classical pathway. We will
therefore refer to this as cell death with apoptotic features.
3.6. Early myotubes expressing α-actin mutants can also undergo cell
death with apoptotic features
As pointed out above, in case of mutant transfections, the number
of fused myotubes was often reduced. This is because dying myotubes
retract from plates, round up and detach rapidly. Therefore, monitor-
ing cell death directly in cultured myotubes is more difﬁcult. Still the
blebbing phenomenonwas observed at the earlymyotube stage. Some
of the myotubes transfected with mutants α-act I64N, I136M, A138P,
L140P, D154N or D286G displayed blebs at their sarcolemma (Fig. 6A–
F, Movie S5). For givenmutants, blebs are either small, big or consist of
piles of multiple stacked small blebs. The presence of these blebs
suggests that the cell death with apoptotic features, observed in
differentiating myoblasts, also occurs at later stages of differentiation.
Evidence for this is presented in Fig. 6, where myotubes transfected
with act L140P, display diffusely distributed cytochrome c in the
sarcoplasma of some myotubes (Fig. 6E). This is in contrast with
untransfected (Fig. 6E) or WT actin expressing myotubes (Fig. 6F)
where the cytochrome c staining is punctuate and distinct. We saw
the same diffuse staining in retracting myotubes expressing act A138P
(Fig. 6G). Moreover in elongated myotubes, presumably representing
an early stage of cell death before retracting and rounding, we saw an
accumulation of mitochondria to the perinuclear region on cyto-
chrome c staining. This is an early indication of apoptosis in several
other cell types [29,30] (Fig. 6H). Myotubes transfected with α-actin
A138P sometimes displayed increased perinuclear endo G staining
(Fig. 6J,L, Movie S6) even after rounding up (Fig. 6K), whereas in WT
myotubes this does not occur (Fig. 6I). These results show that
induction of cell death can occur in differentiating myoblasts as well
as in myotubes in culture expressing particular α-actin mutants
causing NM.
3.7. Does the degree of induction of cell death with apoptotic features
correlate with rod or aggregate formation capacity of the mutants?
The data presented above show that the investigated α-actin
mutants, which are associated with NM induce various cell death
related phenotypes; however, the number of dying cells is different.
Therefore, we analysed if this correlates (or inversely correlates) with
induction of hallmark phenotypes of nemaline myopathy: rods and
aggregates, in ﬁbroblasts or in muscle cells.
α-act H40Y, V163L [16], K336I and S348L (Fig. 7A,B) induce in
many ﬁbroblasts intranuclear rods (that stain with phalloidin) but
only V163L does this to a similar extent inmyoblasts and in a few cases
in nascent and fused myotubes (Fig. 7C–E). For the other three
mutants, rod formation is more sporadic and also not always in the
nucleus (Fig. 7F,G). Similarly, for α-act I64N [16], D179G and V370F
Fig. 5. The observed cell death is associated with apoptotic features in myoblasts. (A) Rounded myoblast expressing myc-α-act A138P showing a fragmented nucleus. (B) A blebbing
myoblast and (C) a rounded up myoblast at day F+4 expressing myc-α-act A138P (green) show intense and/or diffuse cytoplasmic cytochrome c staining (red, compare intensities
with neighbouring non-transfected cells), which is indicative of apoptosis, whereas differentiating myoblasts at day F+4 expressing WT myc-α-actin (D, green) show distinct
punctuate and weaker cytochrome c staining (red). (E) Optical section (Apotome) of a round myoblast expressing myc-α-act A138P (green) with blebs and nuclear endo G
localization (red); the DAPI staining showing the nucleus is in blue. (F) confocal image of differentiatingmyoblast expressingWTmycα-αct (red) showing punctuate endoG staining
(green). (G) Differentiated myoblast expressing myc-α-act A138P orWTmyc-α-act (green) with nuclear AIF localization (red) and aWTexpressing cell (H). Bars, 10 μm. (I) Average
ﬂuorescencemeasurement after cleaved caspase 3 immunostaining (see Fig. S2) shows no signiﬁcant staining inWTand A138Pmyc-α-act expressing cells, compared to staurosporin
incubated cells. (J) Cleaved caspase 3 blot of lysates of Sol8 expressing α-actin WT and A138P. The 17 and 19 kDa fragments of cleaved caspase 3 are seen in lysates of NIH stimulated
with 1 μM staurosporin (STS) as positive control. (K,L) Graph indicating the percentage of rounded blebbing α-actin mutant expressing cells in the transfected populations at stage
F+4 of WT and A138P expressing myc-α-act upon treatment with the pancaspase inhibitor ZVAD-FMK (5 and 10 μM) (K) or with the calpain inhibitor PD150606 (50 μM) (L).
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hardly inmyoblasts ormyotubes (Fig. S1). Formyotubes expressingα-
act D286G, sometimes cytoplasmic or intranuclear rods are observed
(Fig. 7H,I). In general the rods in myotubes do not stain for α-actinin
(Fig. 7D) or troponin T (Fig. 7E,F) but consist of F-actin as shown by
phalloidin staining (Fig. 7C). However, the propensity for rod
formation appears not to correlate with the degree of induction of
cell death, e.g. the strong rod inducing mutant α-act V163L appears to
induce a similar degree of cell death than some mutants that do not
induce rods, like α-act I136M.
The mutants with compromised ATP-binding α-act D154N (this
study) and G15R and V163L [16] display abundant phalloidin positive
aggregates in myoblasts (e.g. G15R and D154N in Fig. 8A–B) and this
parallels the observation for these mutants in ﬁbroblasts ([16] and
data not shown). Most of thesemutants are to some extent also able to
incorporate in actin ﬁbers in cells consistent with their in vitro
copolymerisation capacity (Table 1 and [16]). In differentiating
myoblasts andmyotubes the aggregates appear clustered as thickened
ﬁbers, which do not stain with α-actinin (Fig. 8C–F, see also [15] for
G15R-GFP and V163L-GFP). In sporadic cases we managed to keep
myotubes long enough in culture to obtain the striated pattern, typical
for the sarcomere, as is shown in Fig. 8G for F+11 myotubes
expressing WT-α-actin. In such F+11 myotubes expressing the
mutants α-act D154N (Fig. 8H), V163L (Fig. 8I), and D286G (Fig. 8J)
the thickened ﬁbers become more pronounced and seem to disturb
sarcomere formation. Again however there is no clear correlation
between the aggregate phenotype and the degree of apoptosis
induction since e.g. the mutant α-act D154N induces a substantial
degree of cell deathwhereas for themutantα-act G15R this is equal to
WT-α-actin.
4. Discussion
4.1. NM causing α-actin mutants induce cell death with apoptotic
features in cultured muscle cells
By studying a new series of NM causing α-actin mutants we
unexpectedly discovered that several of these mutants induce cell
death in differentiating muscle cells. This seems to happen regardless
of the subtype of NM, and also regardless of the biochemical and
cytoskeletal phenotype of the mutants. 13 out of 15 of the investigated
mutants induce cell death in differentiating myoblasts and early
myotubes. Since this phenotypewas not a selection criteria for initially
studying these mutants we deduce that induction of cell death in
muscle cells by NM causingα-actin mutants may be a general process.
Although we did not observe hallmarks described for apoptosis,
such as DNA fragmentation, phosphatidyl externalization and
increased caspase activity, we could ﬁnd several apoptotic related
features: cells become rounded up, display blebbing and nuclear
condensation. We also observed perinuclear accumulation of mito-
chondria, release of cytochrome c from mitochondria and transloca-
tion of the apoptosis markers Endo G and AIF to the nuclei or to their
periphery (reviewed by [25]) [23,24]. The lack of increased caspase
activity and the fact that adding a calpain inhibitor to A138P
expressing cells reduced cell death suggests activation of a caspase-
independent pathway in mutant expressing cells. This is consistentFig. 6. Apoptosis also occurs at the myotube stage. Examples of various apoptosis related phe
expression ofmyc-α-act I64N; (B) sol8myotube displaying blebs upon expression ofmyc-α-a
pinched of “vesicle-like structures”were observed; (D) a twisted primary myotube expressin
troponin T staining in (B–D); images are confocal. (E) Myotube expressing myc-α-act L1
cytochrome c staining (red) whereas myotubes expressing WT myc-α-actin (F, green) show
myotube (G) or elongated myotube (H) expressing myc-α-act A138P (green) with diffuse
images of myotubes transfected withWTmyc-α-actin, with regular punctate endo G staining
A138P (green), with nuclear (arrow) and perinuclear enriched endo G staining (red). (K)
containing multiple nuclei where endo G (red) is partly translocated to these nuclei (blue)
perinuclear enriched endo G staining (red). Bars, 20 μm.with the notions that caspase-independent, but calpain-dependent
pathways in muscle tissue are more important [24] and that post-
mitotic apoptosis, especially in muscle, is different from apoptosis in
dividing cells. The latter is in agreement with the lack of apoptosis in
ﬁbroblasts ([15,16], this study) or undifferentiated myoblasts (data
not shown) upon expressing these muscle actin mutants.
The fact that inhibiting caspases increase cell death, both in WT
and mutant expressing differentiating myoblasts is somewhat
surprising but also argues for a caspase-independent pathway of
apoptosis in the mutant expressing cells. Caspase inhibition drama-
tically increases the number of unfused cells, indicating a certain level
of caspase activity not leading to apoptosis is required for myoblast
fusion [31,32].
4.2. Why are the α-actin mutants causing cell death with
apoptotic features?
An obvious explanation is a functional imbalance betweenWT and
mutant α-actin. This may, however, occur in several ways. Mutants α-
act L140P and G146D are arrested on the cellular folding machinery
and may thereby interfere with folding of endogenous WT actin
ultimately resulting in less functional actin. Less stable mutant
monomers may partition preferentially to complexes in which they
are more stable (i.e. ﬁlamentous structures in aggregates or rods) and
thereby become occluded from interaction with the regular muscle
actin structures, for instance during z-body formation. Mutants with
copolymerization defects may affect this important process during
differentiation. Thereforeα-actin mutants may stimulate cell death by
generating aberrant actin structures, e.g. by altered functional G/F-
actin ratios. This parallels the observation that the addition of drugs,
such as jasplakinolide and cytochalasin D, respectively stabilizing and
destabilizing the actin cytoskeleton, results in increased apoptosis in
various cell lines [33,34]. If abnormal actin structures induce cell
death, it is tempting to speculate there is a sensor for cytoskeletal
integrity during muscle differentiation, the nature of which remains
however to be determined.
4.3. Fiber loss in NM-patient muscle might be caused by cell death of
differentiating muscle cells expressing α-actin mutants
Our data open a scenario in which patients may have increased
proportions of dying muscle cells. Demonstrating the occurrence of
cell death inmuscle tissue of patients is, however, difﬁcult, since dying
(apoptotic) cells are rapidly eliminated by phagocytosis by resident
cells to avoid inﬂammatory reactions [35,36]. This is likely the reason
why increased cell death, or apoptosis has not yet been uncovered in
NM muscle biopsies. Yet, it has been shown that apoptotic mechan-
isms occur in various other myopathies and in muscle ﬁber atrophy in
patients [35–37] or in rodent models. It also has been shown that
calpains are involved in different types of muscle atrophy, such as
Duchenne muscular dystrophy, limb-girdle muscular dystrophy and
sarcopenia (reviewed in [38]).
Of relevance is that in rat models of age-related atrophy the EndoG
and AIF content is increased [39,40] suggesting caspase-independent
cell death contributes to preferential loss of type II muscle ﬁbers
during sarcopenia [24,41]. This is consistent with both the commonlynotypes for several mutants are presented. (A) Primary myotube displaying blebs upon
ct I136M; (C) primarymyotube expressingmyc-α-act D154N, in addition to small blebs,
g myc-α-act D286G displays big blebs. Green: myc staining, red:α-actinin staining in A,
40P (green) undergoing apoptosis as deduced from membrane blebbing and diffuse
distinct punctuate cytochrome c staining (red). (G, H) Confocal image of a retracting
staining (G) perinuclear accumulation (H) of cytochrome c staining (red). (I) Confocal
(red); the nucleus is in blue. (J) Confocal image of myotube transfected with myc-α-act
Optical section showing rounded up cells transfected with myc-α-act A138P (green),
. (L) Retracting myotube transfected with myc-α-act A138P (green), with nuclear and
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our observation that expression of α-actin mutants induces AIF and
Endo G mediated cell death in cell cultures. Additionally, biopsies of aNM-patient with mutation G268D showed that muscle tissue was
progressively replaced by connective and fat tissue [42], whichmay be
explained by cell death. Such ﬁbrosis and adiposis is also a common
feature in the dystrophies mentioned above that are associated with
calpain-dependent cell death [43,44]. Moreover induction of cell
death bymutations leading to NMmay not be restricted toα-actin. An
NM mouse model carrying the tropomyosin-3 mutation M9R showed
upregulation of cell death proteins in two types of muscle, next to
degeneration of ﬁbers, abnormal mitochondria and delayed muscle
maturation [45]. This also raises the possibility that the loss of muscle
tissue triggers regeneration through the activation of satellite cells to
terminal differentiation. In these stimulated cells the expression of the
mutant actin could lead to calpain-dependent cell death and thus to
less efﬁcient muscle repair.
4.4. Cell death versus other NM associated phenotypes
Our data suggest that cell death is a common phenotype of
differentiating muscle cells expressing NM causing α-actin mutants.
Yet this may not be the only defect in NM. Indeed for two mutants, α-
act G15R andD286D, we found no evidence for post-mitotic cell death.
We cannot exclude cell death occurring at later stages of differentia-
tion but the fact that these mutants produce thickened ﬁbers suggests
that disturbedmuscle ultrastructuremay also cause NM. Indeed, some
myotubes expressing cell death inducing mutants (α-act D154N,
V163L), escape the process and display abnormal actin-based
structures such as thickened ﬁbers. This leaves open the possibility
that both phenotypes lead to muscle weakness albeit via different
routes. Other examples where cell death likely does not contribute to
NM are the recessive lethal mutations. Themutant proteins are folding
defective [16] and newborns die because they have no functional
striated muscle α-actin.
For the mutants we tested, we found no correlation between the
severity of the disease and the number of dying cells in cell cultures.
This is consistent with the fact that the presence of muscle ﬁber
atrophy was also not correlated with the clinical presentation of NM
patients in a large-scale study [1]. One might however expect that
increased cell death is most important in severe NM, where cell death
reduces the muscle mass dramatically, resulting in mortality short
after birth. As is shown in a mouse model with a α-tropomyosin
mutation, in milder forms of NM, muscle function might increase
through exercise [46], suggesting cell death might be less prominent
here. However, we think cell death is a common phenotype partly
responsible for the observed atrophy and may, perhaps indirectly, be
responsible for muscle weakness in NM patients.
Our discovery of calpain-dependent cell death as a new and fairly
common phenotype induced by α-actin mutants, support the more
current view that rods and aggregates are not the major cause of NM
pathogenesis [45,46]. Indeed, for most of the mutants we observed
that rod formation is less frequent in differentiating muscle cells
than in ﬁbroblasts, which were initially used to characterize NM
causing α-actin mutants ([16] and this study). In addition, it has
been reported that hypotonia manifests itself in NM patients before
rods become visible in biopsies [1,47] and that the proportion ofFig. 7. Several α-actin mutants induce actin rod formation in cell culture. Myc-α-act
K336I (A) and myc-α-act S348L (B) induce intranuclear rod formation in NIH3T3
ﬁbroblasts. (C–E) Examples of rod formation induced by expression of myc-α-act V163L
in (C) undifferentiated Sol8 myoblasts (intranuclear rods); in (D) a nascent myotube
full of rods, in (E) a primary myotube (intranuclear rods); (F,G) primary myotube
expressing myc-α-act K336I display sometimes intranuclear rod formation (F) or
cytoplasmic rod formation (G). (H,I) Myotubes expressing myc-α-act G286D display
intranuclear (H) or cytoplasmic (I) rod formation. Green in (A–G) corresponds to myc
staining, red to phalloidin staining in (A–C), to α-actinin staining in (D) and (G) or
troponin T staining in (E) and (F) and blue to TO-PRO-3 staining in (C). (H) and (I) are
myc staining. Bars, 20 μm.
Fig. 8. Actin mutants with compromised ATP-binding cause aggregate formation. (A, B) Sol8 myoblasts expressing myc-α-act G15R (A) or myc-α-act D154N (green) (B) have
phalloidin (red) positive aggregates. Sol8 myotubes (F+4) expressing myc-α-act G15R (C) or myc-α-act D154N (D) have thickened ﬁbers containing the mutant as do Sol8 myotube
(F+4) expressing myc-α-act V163L (E). (G) Sol8 myotube (F+11) expressingWT-α-actin displays the regular striation patternwhereas in Sol8 myotube (F+11) expressing myc-α-
act D154N (H), Sol8 myotube (F+11) expressingmyc-α-act V163L (I) and Sol8 myotube (F+11) expressing myc-α-act D286G (J) is disturbed and thickened ﬁbers are present. Green
in (C–H) corresponds to myc staining and red to α-actinin staining, myc staining in (I) and (J). Bars, 20 μm.
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weakness [2]. Therefore actin rod formation (and aggregate forma-
tion), may be a secondary effect and perhaps a way for the cell to get
rid of defective actins, as rods are also found in brains of dystonia
patients carrying the β-actin mutation R183W [48]. The assumption
that actin rods and aggregates may be secondary effects does notmean they are harmless, since patient biopsies show that rods or
aggregates severely disturb muscle ultrastructure (see e.g. [49] Fig. 3
and [42] Fig. 1 for rods, and [50] for aggregates caused by α-act
D154N). This suggests that cytoplasmic rods and aggregates may
also contribute to malfunction of muscles at later stages of the
disease.
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In the present study, a picture emerges that calpain involved muscle
cell death may be a major, common and primary defect induced by NM
causing dominant negative α-skeletal muscle actin mutants. In this
scenario, this should lead to muscle ﬁber loss which is consistent with
observed atrophy in patients. However, we consider it unlikely that this
is the sole cause of this heterogeneous disease, since cell death is
usually not the only phenotype observed in cell cultures and, depending
on the particular mutant a signiﬁcant proportion of cells escape cell
death. Those that do, display major ultrastructure disorganisation.
Therefore both phenomena can contribute to muscle weakness.
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